Qualitest Pharmaceuticals has received approval from the Food and Drug Administration for Myzilra tablets, an oral contraceptive.


Qualitest Pharmaceuticals, Myzilra tablets, oral contraceptive, levonorgestrel and ethinyl estradiol


















































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Qualitest cleared to market Myzilra tablets

November 29th, 2011

HUNTSVILLE, Ala. – Qualitest Pharmaceuticals has received approval from the Food and Drug Administration for Myzilra tablets, an oral contraceptive.

The company said Monday that the FDA approved Myzilra tablets (levonorgestrel and ethinyl estradiol) 0.05 mg/0.03 mg, 0.075 mg/0.04 mg, 0.125 mg/0.03 mg in a 28-day triphasic regimen.

Total sales for Myzilra tablets in the United States for the 12 months ended Sept. 30 were approximately $34.4 million, according to IMS Health data cited by Qualitest.

Advertisement